Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
Insulin-induced hypoglycemia is a major treatment barrier in type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon. Varying glucose over the range of concentrations that occur physiologically between the fed and fuel-depri...
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
eLife Sciences Publications
2021
|